氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究*

doi:10.3969/j.issn.1672-5069.2022.05.005

摘要/Abstract

摘要： 目的观察氧化苦参碱(OMT)干预对非酒精性脂肪性肝病(NAFLD)大鼠肝脏的保护作用。方法随机将40只SD大鼠分为对照组10只、模型组10只、OMT干预组10只和辛伐他汀干预组10只,采用高脂饮食饲养建立NAFLD模型,自第9 w开始分别给予OMT或辛伐他汀灌胃至16 w。采用ELISA法检测血清白细胞介素-1β(IL-1β)、IL-6、IL-10和肿瘤坏死因子-α(TNF-α)水平。取肝组织匀浆,检测超氧化物歧化酶(SOD)、还原型谷胱甘肽(GSH)和丙二醛(MDA)水平。结果 OMT干预组大鼠体质量和肝质量分别为(610.3±9.4)g和(11.6±0.7)g,显著低于模型组【分别为(631.8±13.9)g和(13.9±0.6)g,P<0.05】;血清ALT和AST水平分别为(78.9±7.0)U/L和(120.4±11.3)U/L,显著低于模型组【分别为(96.7±11.4)U/L和(183.1±25.9)U/L,P<0.05】;血清TC、TG和LDL水平分别为(2.0±0.2)mmo/L、(2.2±0.1)mmo/L和(1.0±0.1)mmo/L,显著低于模型组【分别为(2.4±0.2)mmo/L、(2.8±0.2)mmo/L和(1.2±0.2)mmo/L,P<0.05】;血清IL-1β、IL-6和TNF-α水平分别为(6.4±1.8)pg/ml、(63.7±8.5)pg/ml和(13.9±1.9)pg/ml,显著低于模型组【分别为(13.9±8.4)pg/ml、(149.8±12.0)pg/ml和(36.5±2.9)pg/ml,P<0.05】,而血清IL-10水平为(42.3±2.0)pg/ml,显著高于模型组【(18.9±1.9)pg/ml,P<0.05】;肝组织匀浆SOD和GSH水平分别为(22.3±2.1)μg/mg和(26.0±2.1)U/mg,显著高于模型组【分别为(17.5±1.9)μg/mg和(15.8±1.8)U/mg,P<0.05】,而MDA水平为(17.9±2.2)nmol/mg,显著低于模型组【(23.8±2.7)nmol/mg,P<0.05】。结论氧化苦参碱可有效保护NAFLD大鼠肝功能,降低血脂水平,可能与其抗炎和抗氧化应激作用有关。

关键词: 非酒精性脂肪性肝病, 氧化苦参碱, 肝脂肪变, 大鼠

Abstract: Objective The aim of this experiment was to observe the protective effect of oxymatrine (OMT) on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases (NAFLD). Methods 40 SD rats were randomly divided into control, model, OMT –intervened and simvastatin-intervened groups, with 10 rats in each. The NAFLD model was established by high-fat diet feeding. Since 9^th week, the normal saline, OMT or simvastatin was given by gavage, and the management continued to 16^th week. Serum interleukin-1β (IL-1β), IL-6, IL-10 and tumor necrosis factor-α (TNF-α), and liver homogenate superoxide dismutase (SOD), reduced glutathione (GSH) and malondialdehyde (MDA) levels were detected. Results The body mass and liver mass in OMT-intervened group were(610.3±9.4)g and (11.6±0.7)g, significantly lower than [(631.8±13.9)g and (13.9±0.6)g, respectively, P<0.05] in the model; serum ALT and AST levels were(78.9±7.0)U/L and (120.4±11.3)U/L, significantly lower than [(96.7±11.4)U/L and (183.1±25.9)U/L, respectively, P<0.05] in the model; serum TC, TG and LDL levels were (2.0±0.2)mmo/L, (2.2±0.1)mmo/L and (1.0±0.1)mmo/L, significantly lower than [(2.4±0.2)mmo/L, (2.8±0.2)mmo/L and (1.2±0.2)mmo/L, respectively, P<0.05] in the model group; serum IL-1β, IL-6 and TNF-α levels were (6.4±1.8)pg/ml, (63.7±8.5)pg/ml and (13.9±1.9)pg/ml, significantly lower than [(13.9±8.4)pg/ml, (149.8±12.0)pg/ml and (36.5±2.9)pg/ml, respectively, P<0.05], while serum IL-10 level was (42.3±2.0) pg/ml, significantly higher than [(18.9±1.9)pg/ml, P<0.05] in the model; the liver homogenate SOD and GSH levels were (22.3±2.1)μg/mg and (26.0±2.1)U/mg, significantly higher than [(17.5±1.9)μg/mg and (15.8±1.8)U/mg, respectively, P<0.05] while MDA level was (17.9±2.2)nmol/mg, significantly lower than [(23.8±2.7)nmol/mg, P<0.05] in the model. Conclusion Oxymatrine could protect the liver function of rats with NAFLD and reduce blood lipids levels, which might be related to its anti-inflammatory and anti-oxidative stress effects.

Key words: Non-alcoholic fatty liver diseases, Oxymatrine, Steatosis, Rats

曾婷, 雷向阳, 白晓苏. 氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 624-627.

Zeng Ting, Lei Xiangyang, Bai Xiaosu. Protective effect of oxymatrine on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases[J]. Journal of Practical Hepatology, 2022, 25(5): 624-627.

参考文献

[1]Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease:Clinical prediction rules and blood-based biomarkers. J Hepatol, 2018,68(2):305-315.
[2]Abenavoli L, Greco M, Milic N,et al. Effect of Mediterranean diet and antioxidant formulation in non-alcoholic fatty liver disease:A randomized study. Nutrients, 2017,9(8):870.
[3]Shimizu M, Suzuki K, Kato K,et al. Evaluation of the effects of dapagliflozin,a sodium-glucose co-transporter-2 inhibitor,on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab, 2019,21(2):285-292.
[4]Mansour-Ghanaei F, Pourmasoumi M, Hadi A,et al. Efficacy of curcumin/turmeric on liver enzymes in patients with non-alcoholic fatty liver disease:A systematic review of randomized controlled trials. Integr Med Res, 2019,8(1):57-61.
[5]Jiang X, Xie L, Huang C,et al. Oral oxymatrine for hepatitis B cirrhosis:A systematic review protocol. Medicine (Baltimore), 2018,97(49):e13482.
[6]An Z, Li J, Yu J,et al. Neutrophil extracellular traps induced by IL-8 aggravate atherosclerosis via activation NF-κB signaling in macrophages. Cell Cycle, 2019,18(21):2928-2938.
[7]Pervez MA, Khan DA, Ijaz A,et al. Effects of delta-tocotrienol supplementation on liver enzymes,inflammation,oxidative stress and hepatic steatosis in patients with nonalcoholic fatty liver disease. Turk J Gastroenterol, 2018,29(2):170-176.
[8]顾立梅,曹培让,顾超,等. 非酒精性脂肪肝中医证型及临床生化指标相关性研究. 南京中医药大学学报,2019,35(6):738-740.
[9]Shen CY, Jiang JG, Yang L,et al. Anti-ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine:pharmacological mechanisms and implications for drug discovery. Br J Pharmacol, 2017,174(11):1395-1425.
[10] 王艳,苏峰,李园园,等.蜂毒溶血肽改善非酒精性脂肪肝大鼠肝组织脂肪沉积作用及其机制研究.实用肝脏病杂志,2019,22(4):474-477.
[11] Korovljev D, Stajer V, Ostojic J,et al. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease:a randomized controlled pilot trial. Clin Res Hepatol Gastroenterol, 2019,43(6):688-693.
[12] Zhang H, Yang L, Wang Y,et al. Oxymatrine alleviated hepatic lipid metabolism via regulating miR-182 in non-alcoholic fatty liver disease. Life Sci, 2020,257(11):118090.
[13] Zhou L, Wang SB, Chen SG,et al. Prognostic value of ALT,AST,and GGT in hepatocellular carcinoma with B-type hepatitis-associated cirrhosis after radical hepatectomy. Clin Lab, 2018,64(10):1739-1747.
[14] Shen Y, Shen X, Cheng Y,et al. Myricitrin pretreatment ameliorates mouse liver ischemia reperfusion injury. Int Immunopharmacol, 2020,89(Pt A):107005.
[15] Shen B, Feng H, Cheng J,et al. Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathways. J Cell Mol Med, 2020,24(9):5097-5108.
[16] Jin X, Fu W, Zhou J,et al. Oxymatrine attenuates oxidized low-density lipoprotein-induced HUVEC injury by inhibiting NLRP3 inflammasome-mediated pyroptosis via the activation of the SIRT1/Nrf2 signaling pathway. Int J Mol Med, 2021,48(4):187.
[17] 艾正琳,谢步善,姚树坤.苦参碱治疗非酒精性脂肪性肝炎大鼠的效果观察.临床肝胆病杂志,2016,32(11):2163-2166.
[18] Guan B, Chen R, Zhong M,et al. Protective effect of oxymatrine against acute spinal cord injury in rats via modulating oxidative stress,inflammation and apoptosis. Metab Brain Dis,2020,35(1):149-157.
[19] 余小虎,朱金水,顾国妹,等.氧化苦参碱联合二甲双胍对非酒精性脂肪肝患者胰岛素抵抗及血清TNFα的影响. 临床肝胆病杂志,2007,23(3):195-196.
[20] Liu X, Wang D, Yang W,et al. Oxymatrine exerts anti-fibrotic effects in a rat model of hepatic fibrosis by suppressing endoplasmic reticulum stress. J Int Med Res, 2020,48(10):300060520961681.

氧化苦参碱对非酒精性脂肪性肝病大鼠肝脏保护作用研究^*

Protective effect of oxymatrine on liver steatosis in rats with high-fat-induced non-alcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘彦彤, 姚杨, 卢博. 荷叶调脂疏肝汤对非酒精性脂肪性肝病患者脂代谢的影响研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 657-660.
[2]	奚佳颖, 汤佳美, 刘玲玉, 王韦. 超声三维斑点追踪技术评价非酒精性脂肪性肝病合并2型糖尿病患者左心功能研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 661-664.
[3]	潘飞, 寿涓, 张冬青. 不同他汀类药物治疗非酒精性脂肪性肝病合并高脂血症患者效果分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 665-668.
[4]	王慧, 汤展, 常文娟, 芦超. 非肥胖型与肥胖型非酒精性脂肪性肝病患者代谢特征和肝脂肪变程度比较^*[J]. 实用肝脏病杂志, 2022, 25(5): 669-672.
[5]	陈梦绮, 范建高. 美国非酒精性脂肪性肝病诊断与治疗临床实践指南简介^*[J]. 实用肝脏病杂志, 2022, 25(5): 0-S16.
[6]	王晴, 张利莉. 当2型糖尿病遇上非酒精性脂肪性肝病:1+1＞2 ？[J]. 实用肝脏病杂志, 2022, 25(4): 460-463.
[7]	汪晓燕, 钟雪玉, 吴春燕. 沙格列汀干预非酒精性脂肪性肝病合并2型糖尿病大鼠肝组织AMPK/mTOR-TFEB自噬信号通路蛋白表达变化^*[J]. 实用肝脏病杂志, 2022, 25(4): 476-479.
[8]	张文彦, 刘芳, 刘梦露, 陈德喜, 张晶, 时红波, 于海滨. 非酒精性脂肪性肝病患者血浆外泌体差异蛋白分析^*[J]. 实用肝脏病杂志, 2022, 25(4): 521-525.
[9]	李亚文, 周军. 化痰祛湿疏肝方联合辛伐他汀治疗非酒精性脂肪性肝病痰湿内阻证患者临床疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 526-529.
[10]	年福临, 鲁晓岚. 糖尿病与非酒精性脂肪性肝病^*[J]. 实用肝脏病杂志, 2022, 25(3): 314-317.
[11]	王诗淞, 林辉雄, 张泰胜, 董俪雯, 王英霞, 林秋香. 二甲双胍联合达格列净治疗T2DM合并NAFLD患者疗效及血清二肽基肽酶4和C肽变化^*[J]. 实用肝脏病杂志, 2022, 25(3): 379-382.
[12]	蔡冬梅, 吴文娟, 姜亦伦, 居敏昊. CT检测非酒精性脂肪性肝病合并高危冠状动脉斑块患者冠状动脉指标临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(3): 383-386.
[13]	周平, 姚登福, 姚敏. NAFLD与肝细胞恶性转化相关研究新进展^*[J]. 实用肝脏病杂志, 2022, 25(2): 157-160.
[14]	侯文靖, 吴广明, 盖慧慧. 三七总皂苷对非酒精性脂肪性肝病小鼠肝组织脂质沉积及NO/iNOS/NF-κB通路的影响^*[J]. 实用肝脏病杂志, 2022, 25(2): 174-178.
[15]	刘尚智, 张志强, 李昇锦. 丹栀逍遥散对D-氨基半乳糖/脂多糖诱导的大鼠急性肝损伤保护作用机制研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 179-182.